Alzamend Neuro Statistics
Total Valuation
Alzamend Neuro has a market cap or net worth of $8.97 million. The enterprise value is $3.35 million.
Important Dates
The next estimated earnings date is Thursday, December 11, 2025, after market close.
| Earnings Date | Dec 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Alzamend Neuro has 3.80 million shares outstanding. The number of shares has increased by 1,121.34% in one year.
| Current Share Class | 3.80M |
| Shares Outstanding | 3.80M |
| Shares Change (YoY) | +1,121.34% |
| Shares Change (QoQ) | +196.09% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 0.96% |
| Float | 3.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.03
| Current Ratio | 6.03 |
| Quick Ratio | 5.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -732.97 |
Financial Efficiency
Return on equity (ROE) is -302.25% and return on invested capital (ROIC) is -188.65%.
| Return on Equity (ROE) | -302.25% |
| Return on Assets (ROA) | -97.46% |
| Return on Invested Capital (ROIC) | -188.65% |
| Return on Capital Employed (ROCE) | -116.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$976,194 |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.71% in the last 52 weeks. The beta is -0.28, so Alzamend Neuro's price volatility has been lower than the market average.
| Beta (5Y) | -0.28 |
| 52-Week Price Change | -83.71% |
| 50-Day Moving Average | 2.39 |
| 200-Day Moving Average | 5.03 |
| Relative Strength Index (RSI) | 48.76 |
| Average Volume (20 Days) | 132,309 |
Short Selling Information
The latest short interest is 104,714, so 2.75% of the outstanding shares have been sold short.
| Short Interest | 104,714 |
| Short Previous Month | 209,633 |
| Short % of Shares Out | 2.75% |
| Short % of Float | 2.77% |
| Short Ratio (days to cover) | 0.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.23M |
| Pretax Income | -6.24M |
| Net Income | -6.83M |
| EBITDA | -6.17M |
| EBIT | -6.23M |
| Earnings Per Share (EPS) | -$7.15 |
Full Income Statement Balance Sheet
The company has $5.62 million in cash and n/a in debt, giving a net cash position of $5.62 million or $1.48 per share.
| Cash & Cash Equivalents | 5.62M |
| Total Debt | n/a |
| Net Cash | 5.62M |
| Net Cash Per Share | $1.48 |
| Equity (Book Value) | 5.34M |
| Book Value Per Share | 1.70 |
| Working Capital | 4.95M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$7.88 million and capital expenditures -$210,000, giving a free cash flow of -$8.09 million.
| Operating Cash Flow | -7.88M |
| Capital Expenditures | -210,000 |
| Free Cash Flow | -8.09M |
| FCF Per Share | -$2.13 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,121.34% |
| Shareholder Yield | -1,121.34% |
| Earnings Yield | -76.16% |
| FCF Yield | -90.12% |
Analyst Forecast
The average price target for Alzamend Neuro is $42.00, which is 1,679.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $42.00 |
| Price Target Difference | 1,679.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2025. It was a reverse split with a ratio of 1:9.
| Last Split Date | May 12, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |